Corcept Therapeutics Incorporated (CORT) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Total Revenue Chart for Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT) revenue for FY2025 was USD 761.4M, a 12.8% change from FY2024. Corcept Therapeutics Incorporated's revenue grew from USD 294.0K in 2006 to USD 761.4M in 2025 (258882.0% over 19 years). Earnings per share moved from USD -0.39 in 2011 to USD 0.87 in 2022. Revenue compound annual growth rate: 5-year CAGR of 16.6%, 10-year CAGR of 31.2%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$12.93B
Implied Share Price
$119.57
Enterprise Value
$11.89B
Revenue (TTM)
$830.81M
EBITDA
$8.08M
Profit Margin
6.64%
Trailing P/E
271.75
Forward P/E
19.30
Price/Book (MRQ)
18.00
Price/Sales (TTM)
15.56
EV/EBITDA
1405.48
EV/Revenue
14.93
Dividend Yield
—
Book Value
$6.54
Free Cash Flow (FY2025)
$141.78M
Free Cash Flow Yield
1.10%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.